Page 138 - 202016

位患者开始给药[J].国际药学研究杂志，2019，46（11）： 杂志，2018，51（4）：247-250.
861. [42] 王平.小剂量甲泼尼龙联合便携式NB-UVB治白癜风的
[33] MOBASHER P，GUERRA R，LI SJ，et al. Open label 临床疗效观察[D].西宁：青海大学，2018.
pilot study of tofacitinib 2％ for the treatment of [43] BRITTANY U. Jak-inhibitors and UV-B：potential combi-
refractory vitiligo[J]. Br J Dermatol，2020，182（4）： ned therapy for vitiligo[J]. Dermatol Ther，2017，30（5）：
1047-1049. e12531.
[34] LIU LY，STRASSNER JP，REFAT MA，et al. Repigmen- [44] LIU LY，CRAIGLOW BG，DAI F，et al. Tofacitinib for
tation in vitiligo using the Janus kinase inhibitor tofa- the treatment of severe alopecia areata and variants：a
citinib may require concomitant light exposure[J]. J Am study of 90 patients[J]. J Am Acad Dermatol，2017，76
Acad Dermatol，2017，77（4）：675-682. （1）：22-28.
[35] GIANFALDONI S，TCHERNEV G，WOLLINA U，et al. [45] SANDBORN WJ，PANÉS J，D’Haens GR，et al. Safety of
Micro-focused phototherapy associated to janus kinase tofacitinib for treatment of ulcerative colitis，based on 4.4
inhibitor：a promising valid therapeutic option for patients years of data from global clinical trials[J]. Clin Gastr-
with localized vitiligo[J]. Open Access Maced J Med Sci， oenterol Hepatol，2019，17（8）：1541-1550.
2018，6（1）：46-48. [46] SCOTT IC，HIDER SL，SCOTT DL. Thromboembolism
[36] KIM SR，HEATON H，LIU LY，et al. Rapid repigmen- with Janus kinase （JAK） inhibitors for rheumatoid
tation of vitiligo using tofacitinib plus low-dose， arthritis：how real is the risk? [J]. Drug Saf，2018，41（7）：
narrowband UV-B phototherapy[J]. JAMA Dermatology， 645-653.
2018，154（3）：370-371. [47] PICARDO S，SEOW CH. A pharmacological approach to
[37] MCKESEY J，PANDYA A. A pilot study of 2％ tofacitinib managing inflammatory bowel disease during conception，
cream with narrowband ultraviolet B for the treatment of pregnancy and breastfeeding：biologic and oral small
facial vitiligo[J]. J Am Acad Dermatol，2019，81（2）： molecule therapy[J]. Drugs，2019，79（10）：1053-1063.
646-648. [48] CURTIS JR，LEE EB，KAPLAN I，et al. Tofacitinib，an
[38] JOSHIPURA D，ALOMRAN A，ZANCANARO P，et al. oral Janus kinase inhibitor：analysis of malignancies
Treatment of vitiligo with the topical Janus kinase across the rheumatoid arthritis clinical development
inhibitor ruxolitinib：a 32-week open-label extension programme[J]. Ann Rheum Dis，2016，75（5）：831-841.
study with optional narrow-band ultraviolet B[J]. J Am [49] D’AMICO F，PARIGI TL，FIORINO G，et al. Tofacitinib
Acad Dermatol，2018，78（6）：1205-1207. in the treatment of ulcerative colitis：efficacy and safety
[39] KOMNITSKI M，KOMNITSKI A，KOMNITSKI JUNIOR from clinical trials to real-world experience[J]. Therap
A，et al. Partial repigmentation of vitiligo with tofacitinib， Adv Gastroenterol，2019. DOI：10.1177/1756284819-
without exposure to ultraviolet radiation[J]. A Bras Der- 848631.ecollection2019.
matol，2020，95（4）：473-476. [50] WEISSHOF R，AHARONI GOLAN M，SOSSENHEIMER
[40] MOHAMMAD TF，AL-JAMAL M，HAMZAVI IH，et al. PH，et al. Real-world experience with tofacitinib in IBD at
The Vitiligo Working Group recommendations for a tertiary center[J]. Dig Dis Sci，2019，64（7）：1945-1951.
narrowband ultraviolet B light phototherapy treatment of （收稿日期：2020-05-27 修回日期：2020-06-23）
vitiligo[J]. J Am Acad Dermatol，2017，76（5）：879-888. （编辑：罗 瑞）
[41] 许爱娥，高天文.白癜风诊疗共识：2018版[J].中华皮肤科

《中国药房》杂志——RCCSE中国核心学术期刊，欢迎投稿、订阅

·2048 · China Pharmacy 2020 Vol. 31 No. 16 中国药房 2020年第31卷第16期